{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:44:11Z","timestamp":1791305051642,"version":"4.3.1"},"reference-count":31,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: There is insufficient information in the literature on the comparative efficacy and tolerability of methotrexate (MTX) and methylprednisolone (MP) in patients with pulmonary sarcoidosis in assessing primary outcomes and the relapse rate. Purpose: The aim of our study was to evaluate primary and long-term outcomes of using MTX and MP in patients with pulmonary sarcoidosis. Methods: A total of 143 patients with newly diagnosed pulmonary sarcoidosis, verified by high-resolution computed tomography (CT) data, were examined. Corticosteroid (CS) therapy was used in 97 patients using MP at a dose of 0.4 mg\/kg body weight for 4 weeks, followed by a dose reduction to 0.1 mg\/kg by the end of the sixth month. The total duration of CS therapy was 12 months on average. Forty-six patients were treated with MTX at a dose of 10 mg\/week (28) and 15 mg\/week (18) per os for 6 to 12 months. The study of the relapse rate was conducted within 12 months after the CT data normalization in 60 patients after CS therapy and in 24 after MTX treatment. Results: MP treatment was successfully completed in 68 (70.1%), and MTX in 29 (60.4%) patients. In five MP patients (5.2%) and in five (10.9%) MTX, treatment was discontinued due to serious side effects. In seven (7.2%) MP patients and ten (21.7%) MTX patients, treatment required additional therapy due to the lack of efficacy. Progression with MP treatment (17\u201317.5%) was more common than with MTX (2\u20134.3%; Chi square = 4.703, p = 0.031). Relapses after MP therapy were observed in 26 (43.3%) patients, and after MTX therapy in 2 (8.3%; Chi square = 9.450, p = 0.003). Conclusion: In patients with pulmonary sarcoidosis, MTX monotherapy does not differ significantly from MP monotherapy in terms of the level of efficacy and the rate of serious side effects. Increasing the MTX dose from 10 to 15 mg\/week accelerates the rate of regression of sarcoidosis, improves treatment efficacy, and does not affect the rate of serious side effects. When using MTX, there is a significant decrease in the incidence of treatment resistance and the relapse rate.<\/jats:p>","DOI":"10.3390\/diagnostics11071289","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T04:55:40Z","timestamp":1626670540000},"page":"1289","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Efficacy and Tolerability of Methotrexate and Methylprednisolone in a Comparative Assessment of the Primary and Long-Term Outcomes in Patients with Pulmonary Sarcoidosis"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6942-4504","authenticated-orcid":false,"given":"Volodymyr","family":"Gavrysyuk","sequence":"first","affiliation":[{"name":"Department of Interstitial Lung Diseases, National Institute of Phthisiology and Pulmonology Named after F. G. Yanovsky, 10, M. Amosova str., 03038 Kyiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1299-7058","authenticated-orcid":false,"given":"Ievgenia","family":"Merenkova","sequence":"additional","affiliation":[{"name":"Department of Interstitial Lung Diseases, National Institute of Phthisiology and Pulmonology Named after F. G. Yanovsky, 10, M. Amosova str., 03038 Kyiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6497-5267","authenticated-orcid":false,"given":"Yaroslav","family":"Dziublyk","sequence":"additional","affiliation":[{"name":"Department of Interstitial Lung Diseases, National Institute of Phthisiology and Pulmonology Named after F. G. Yanovsky, 10, M. Amosova str., 03038 Kyiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5255-8290","authenticated-orcid":false,"given":"Nataliia","family":"Morska","sequence":"additional","affiliation":[{"name":"Department of Interstitial Lung Diseases, National Institute of Phthisiology and Pulmonology Named after F. G. Yanovsky, 10, M. Amosova str., 03038 Kyiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7875-3561","authenticated-orcid":false,"given":"Nataliia","family":"Pendalchuk","sequence":"additional","affiliation":[{"name":"Department of Interstitial Lung Diseases, National Institute of Phthisiology and Pulmonology Named after F. G. Yanovsky, 10, M. Amosova str., 03038 Kyiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olesia","family":"Bychenko","sequence":"additional","affiliation":[{"name":"Department of Interstitial Lung Diseases, National Institute of Phthisiology and Pulmonology Named after F. G. Yanovsky, 10, M. Amosova str., 03038 Kyiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7590-4704","authenticated-orcid":false,"given":"Nataliia","family":"Vlasova","sequence":"additional","affiliation":[{"name":"Department of Differential Diagnosis of Tuberculosis and Nonspecific Lung Deseases, National Institute of Phthisiology and Pulmonology Named after F. G. Yanovsky, 10, M. Amosova str., 03038 Kyiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"key":"ref_1","first-page":"149","article-title":"ATS\/ERS\/WASOG statement on sarcoidosis. American Thoracic Society\/European Respiratory Society\/ World Association of Sarcoidosis and other Granulomatous Disorders","volume":"16","author":"Hunninghake","year":"1999","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Judson, M.A. (2014). The Diagnosis of Sarcoidosis. Pulmonary Sarcoidosis: A Guide for the Practicing Clinician, Respiratory Medicine, 17, Springer Science + Business Media.","DOI":"10.1007\/978-1-4614-8927-6"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1164\/ajrccm.164.10.2104046","article-title":"Clinical characteristics of patients in a case control study of Sarcoidosis","volume":"164","author":"Baughman","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Judson, M.A. (2014). The Pulmonary Manifestations of Sarcoidosis. Pulmonary Sarcoidosis: A Guide for the Practicing Clinician, Respiratory Medicine, 17, Springer Science + Business Media.","DOI":"10.1007\/978-1-4614-8927-6"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Sharma, O.P., and Mihailovich-Vucinic, V. (2014). Lesions of Sarcoidosis. A Problem Solving Approach, Jaypee Brothers Medical Publishers (P) Ltd.","DOI":"10.5005\/jp\/books\/12119_25"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.itjm.2012.05.002","article-title":"Sarcoidosis: Old certainties and new perspectives","volume":"6","author":"Tana","year":"2012","journal-title":"Ital. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ccm.2004.04.006","article-title":"Pulmonary Sarcoidosis","volume":"25","author":"Baughman","year":"2004","journal-title":"Clin. Chest Med."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Judson, M.A. (2014). The Treatment of Pulmonary Sarcoidosis. Pulmonary Sarcoidosis: A Guide for the Practicing Clinician, Respiratory Medicine, 17, Springer Science + Business Media.","DOI":"10.1007\/978-1-4614-8927-6"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/TCRM.S192922","article-title":"Refractory Sarcoidosis: A Review","volume":"16","author":"Jammiloux","year":"2020","journal-title":"Ther. Clin. Risk Management."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.rmed.2012.01.013","article-title":"The treatment of pulmonary sarcoidosis","volume":"106","author":"Judson","year":"2012","journal-title":"Respir. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.rmed.2009.12.009","article-title":"Pharmacotherapy for pulmonary sarcoidosis: A Delphi consensus study","volume":"104","author":"Schutt","year":"2010","journal-title":"Respir. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/thx.51.3.238","article-title":"British Thoracic Society Sarcoidosis study: Effects of long term corticosteroid treatment","volume":"51","author":"Gibson","year":"1996","journal-title":"Thorax"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1378\/chest.121.1.24","article-title":"Early treatment of study II sarcoidosis improves 5-year pulmonary function","volume":"121","author":"Pietinalho","year":"2002","journal-title":"Chest"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1183\/09031936.00138913","article-title":"Relapses of sarcoidosis: What are they and can we predict who will get them?","volume":"43","author":"Baughman","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1378\/chest.111.3.623","article-title":"Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy","volume":"111","author":"Gottlieb","year":"1997","journal-title":"Chest"},{"key":"ref_16","first-page":"52","article-title":"The late follow-up of chronic sarcoid patients previously treated with corticosteroids","volume":"15","author":"Rizzato","year":"1998","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/CPM.0000000000000136","article-title":"Refractory pulmonary sarcoidosis\u2014Proposal of definition and recommendation for the diagnostic and therapeutic approach","volume":"23","author":"Korsten","year":"2016","journal-title":"Clin. Pulm. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/MCP.0b013e3283642a7a","article-title":"Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: Integrating systematic literature research and expert opinion of sarcoidologists worldwide","volume":"19","author":"Cremers","year":"2013","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_19","first-page":"87","article-title":"Efficacy of azathioprine as second-line treatment of pulmonary sarcoidosis","volume":"16","author":"Lewis","year":"1999","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_20","first-page":"43","article-title":"Lefludomide for chronic sarcoidosis","volume":"21","author":"Baughman","year":"2004","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1183\/09031936.00195010","article-title":"Effectiveness and safety of leflunomide for pulmonary and extrapulmonary sarcoidosis","volume":"38","author":"Sahoo","year":"2011","journal-title":"Eur. Respir. J."},{"key":"ref_22","first-page":"217","article-title":"Effectiveness and tolerability of methotrexate in pulmonary sarcoidosis: A single center real-world study","volume":"36","author":"Fang","year":"2019","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_23","first-page":"1","article-title":"Methotrexate in sarcoidosis: Hematologic toxicity ehcountered in a large cohort over a six year period","volume":"37","author":"Baughman","year":"2020","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.61.8.718","article-title":"Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: Current questions and tentative answers in rheumatology","volume":"61","author":"Buttgereit","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1183\/09031936.06.00105805","article-title":"Corticosteroid treatment in sarcoidosis","volume":"28","author":"Grutters","year":"2006","journal-title":"Eur. Respir. J."},{"key":"ref_26","first-page":"CD001114","article-title":"Corticosteroids for pulmonary sarcoidosis","volume":"2005","author":"Paramothayan","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1702089","DOI":"10.1183\/13993003.02089-2017","article-title":"Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis","volume":"51","author":"Broos","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MAJ.0b013e3181b97635","article-title":"Efficacy of Short-Course, Low-Dose Corticosteroid Therapy for Acute Pulmonary Sarcoidosis Exacerbations","volume":"339","author":"McKinzie","year":"2010","journal-title":"Am. J. Med. Sci."},{"key":"ref_29","first-page":"60","article-title":"Methotrexate is steroid sparing in acute sarcoidosis: Results of a double blind, randomized trial","volume":"17","author":"Baughman","year":"2000","journal-title":"Sarcoidosis Vasc. Diffus. Lung Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.18093\/0869-0189-2020-30-2-213-218","article-title":"Evaluation of the efficacy and safety of methotrexate in progressive sarcoidosis: A retrospective observational study","volume":"30","author":"Vizel","year":"2020","journal-title":"Russ. Pulmonol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Judson, M.A. (2014). Acute Pulmonary Exacerbation of Sarcoidosis. Pulmonary Sarcoidosis: A Guide for the Practicing Clinician, Respiratory Medicine, 17, Springer Science + Business Media.","DOI":"10.1007\/978-1-4614-8927-6"}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/7\/1289\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:31:37Z","timestamp":1760164297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/7\/1289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["diagnostics11071289"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics11071289","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,19]]}}}